SwePub
Sök i LIBRIS databas

  Utökad sökning

(WFRF:(Öberg Kjell 1946 )) pers:(Caplin Martyn)
 

Sökning: (WFRF:(Öberg Kjell 1946 )) pers:(Caplin Martyn) > (2022) > Long-Term Treatment...

  • Hörsch, DieterZent Klin Bad Berka, Ctr Neuroendocrine Tumors, Dept Gastroenterol Endocrinol, Bad Berka, Germany. (författare)

Long-Term Treatment with Telotristat Ethyl in Patients with Carcinoid Syndrome Symptoms : Results from the TELEPATH Study

  • Artikel/kapitelEngelska2022

Förlag, utgivningsår, omfång ...

  • 2021-05-03
  • S. Karger,2022
  • electronicrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:uu-502260
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-502260URI
  • https://doi.org/10.1159/000516958DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Introduction: Telotristat ethyl is indicated for use in combination with somatostatin analogs (SSAs) to treat carcinoid syndrome (CS) diarrhea uncontrolled by SSAs alone in adults, but long-term safety and efficacy data beyond 48 weeks are needed.Objectives: The aims of the study were to evaluate the long-term safety and tolerability of telotristat ethyl and its effect on quality of life (QOL) in patients with CS.Methods: In this phase 3, nonrandomized, multicenter, open-label, long-term extension study (TELEPATH), patients who participated in phase 2 or 3 trials of telotristat ethyl continued treatment at their present dose level (250 or 500 mg thrice daily) for 84 weeks. Safety and tolerability, the primary endpoint, were assessed by monitoring adverse events (AEs), serious AEs, AEs of special interest (AESIs; including liver-related AEs, depression, and gastrointestinal AEs), and deaths. The secondary objective was to evaluate changes in patients’ QOL using validated cancer questionnaires and a subjective global assessment of CS symptoms.Results: In 124 patients exposed to telotristat ethyl for a mean of 102.6 ± 53.2 weeks, the type and frequency of AEs were consistent with those reported in previous trials. The occurrence of AESIs was not related to dosage or duration of therapy. Most AEs were mild to moderate in severity, and no deaths were related to telotristat ethyl. QOL scores remained stable, and the majority of patients reported adequate symptom relief throughout the study.Conclusions: Safety results of TELEPATH support the long-term use of telotristat ethyl in patients with CS diarrhea. Telotristat ethyl was well-tolerated and associated with sustained improvement in QOL scores (NCT02026063). 

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Anthony, LowellUniv Kentucky, Markey Canc Ctr, Lexington, KY USA. (författare)
  • Gross, David J.Hadassah Hebrew Univ Med Ctr, European Neuroendocrine Tumor Soc Ctr Excellence, Dept Med, Endocrine Serv,Neuroendocrine Tumor Unit, Jerusalem, Israel. (författare)
  • Valle, JuanUniv Manchester, Christie NHS Fdn Trust, Manchester, Lancs, England. (författare)
  • Welin, StaffanUppsala universitet,Onkologisk endokrinologi(Swepub:uu)stafweli (författare)
  • Benavent, MartaVirgen del Rocio Univ Hosp, Inst Biomed Sevilla, Med Oncol Dept, Seville, Spain. (författare)
  • Caplin, MartynRoyal Free Hosp, Dept Gastroenterol & Hepatobiliary Med, Pond St Ctr Gastroenterol, London, England. (författare)
  • Pavel, MarianneCharite, Dept Gastroenterol & Hepatol, Berlin, Germany. (författare)
  • Bergsland, EmilyUniv Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA. (författare)
  • Öberg, Kjell,1946-Uppsala universitet,Endokrin tumörbiologi(Swepub:uu)kjellob (författare)
  • Kassler-Taub, Kenneth B.Lexicon Pharmaceut Inc, The Woodlands, TX USA. (författare)
  • Binder, PolinaLexicon Pharmaceut Inc, The Woodlands, TX USA. (författare)
  • Banks, PhillipLexicon Pharmaceut Inc, The Woodlands, TX USA. (författare)
  • Lapuerta, PabloLexicon Pharmaceut Inc, The Woodlands, TX USA. (författare)
  • Kulke, Matthew H.Boston Univ, Sect Hematol Oncol, Boston, MA 02215 USA.;Boston Med Ctr, Boston, MA USA. (författare)
  • Zent Klin Bad Berka, Ctr Neuroendocrine Tumors, Dept Gastroenterol Endocrinol, Bad Berka, Germany.Univ Kentucky, Markey Canc Ctr, Lexington, KY USA. (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Neuroendocrinology: S. Karger112:3, s. 298-3090028-38351423-0194

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy